Prescription Pathways from Initial Medication Use to Triple Therapy in Older COPD Patients: A Real-World Population Study

References

• Soriano JB, Abajobir AA, Abate KH, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691–706. DOI:10.1016/S2213-2600(17)30293-X
   PubMed Web of Science ®Google Scholar
• Barnes PJ, Burney PGJ, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primer. 2015;1:1–21.
   Web of Science ®Google Scholar
• Harrison EM, Kim V. Long-acting maintenance pharmacotherapy in chronic obstructive pulmonary disease. Respir Med X. 2019;1:100009.
   Google Scholar
• December 2019 GI for COLD. GOLD COPD 2020 strategy [Internet]. Guidelines [cited 2020 Jun 26]. Available from: https://www.guidelines.co.uk/respiratory/gold-copd-2020-strategy/455088.article.
   Google Scholar
• Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201(9):e56–e69. DOI:10.1164/rccm.202003-0625ST
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian thoracic society clinical practice guideline on pharmacotherapy in patients with COPD—2019 update of evidence. Can J Respir Crit Care Sleep Med Taylor Francis. 2019;3:210–232.
   Web of Science ®Google Scholar
• Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis. 2015;10:2207–2217.
   PubMed Web of Science ®Google Scholar
• Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US [internet]. COPD. 2016;12:73–83. Available from: https://www.dovepress.com/initiation-of-triple-therapy-maintenance-treatment-among-patients-with-peer-reviewed-article-COPD. DOI:10.2147/COPD.S122013
   Google Scholar
• Safka KA, Wald J, Wang H, et al. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr Pulm Dis Miami Fla. 2016;4:45–55.
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Nuñez A, Solntseva I, et al. Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain. Arch Bronconeumol (Engl Ed). 2021;57(3):205–213. DOI:10.1016/j.arbres.2020.07.032
   PubMed Web of Science ®Google Scholar
• Mapel D, Laliberte F, Roberts MH, et al. A retrospective study to assess clinical charactexeristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting Mono- or combination therapy. COPD. 2017;12:1825–1836. DOI:10.2147/COPD.S129007
   Google Scholar
• Hahn B, Hull M, Blauer-Peterson C, et al. Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respir Med. 2018;139:65–71. DOI:10.1016/j.rmed.2018.04.014
   PubMed Web of Science ®Google Scholar
• Hurst JR, Dilleen M, Morris K, et al. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. COPD. 2018;13:781–792. DOI:10.2147/COPD.S153655
   Google Scholar
• Bogart M, Stanford RH, Reinsch T, et al. Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: a retrospective study. Respir Med. 2018;142:73–80.
   PubMed Web of Science ®Google Scholar
• Meeraus W, Wood R, Jakubanis R, et al. COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners. Int J Chron Obstruct Pulmon Dis. 2019;14:51–63.
   PubMed Web of Science ®Google Scholar
• Hurley J, Johnson NA. The effects of Co-payments within drug reimbursement programs. Can Public Policy Anal Polit. 1991;17(4)[University of Toronto Press, Canadian Public Policy]:473–489. DOI:10.2307/3551708
   Web of Science ®Google Scholar
• eHealth Ontario. 2018. “Ontario laboratories information system.” [cited 2020 Jun 26]. Available from: https://www.ehealthontario.on.ca/for-healthcare-professionals/ontario-laboratories-information-system-olis.
   Google Scholar
• Gershon AS, Wang C, Guan J, et al. Identifying individuals with physcian diagnosed COPD in health administrative databases. COPD. 2009;6(5):388–394. DOI:10.1080/15412550903140865
   PubMedGoogle Scholar
• Gershon A, Croxford R, To T, et al. Comparison of inhaled long-acting β-agonist and anticholinergic effectiveness in older patients with chronic obstructive pulmonary disease: a cohort study. Ann Intern Med. 2011;154(9):583–592.
   PubMed Web of Science ®Google Scholar
• Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Suppl 41):46s–53s. DOI:10.1183/09031936.03.00078002
   Web of Science ®Google Scholar
• Marco FD, Santus P, Terraneo S, et al. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study. Npj Prim Care Respir Med. 2017;27:1–6. Nature Publishing Group.
   PubMed Web of Science ®Google Scholar
• Lane DC, Stemkowski S, Stanford RH, et al. Initiation of triple therapy with multiple inhalers in chronic obstructive pulmonary disease: an analysis of treatment patterns from a U.S. Retrospective database study. J Manag Care Spec Pharm. 2018;24(11):1165–1172.
   PubMed Web of Science ®Google Scholar
• Monteagudo M, Barrecheguren M, Solntseva I, et al. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD. Npj Prim Care Respir Med. 2021;31(1):1–7. DOI:10.1038/s41533-021-00227-x
   PubMed Web of Science ®Google Scholar
• Vetrano DL, Zucchelli A, Bianchini E, et al. Triple inhaled therapy in COPD patients: determinants of prescription in primary care. Respir Med. 2019;154:12–17.
   PubMed Web of Science ®Google Scholar
• Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One. 2014;9(9):e105296. DOI:10.1371/journal.pone.0105296
   PubMed Web of Science ®Google Scholar
• Tavakoli H, Johnson KM, FitzGerald JM, et al. Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada. Int J Chron Obstruct Pulmon Dis. 2019;14:2003–2013.
   PubMed Web of Science ®Google Scholar
• Harries TH, Rowland V, Corrigan CJ, et al. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and Meta-analysis. Respir Res. 2020;21(1):3.
   PubMed Web of Science ®Google Scholar
• Chronic Obstructive Pulmonary Disease: The Quality Standard In Brief - Health Quality Ontario (HQO). Available from: https://www.hqontario.ca/Evidence-to-Improve-Care/Quality-Standards/View-all-Quality-Standards/Chronic-Obstructive-Pulmonary-Disease/The-Quality-Standard-In-Brief.
   Google Scholar